Artios

Drug Discovery · Cambridge, United Kingdom · Founded 2015 · Privately Held (backing)

Developer of novel cancer treatments designed to target the deoxyribonucleic acid (DNA) damage response. Artios is based in Cambridge, United Kingdom and was founded in 2015. It was valued at $260 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $385 million across 1 recorded round; the latest was an $114 million Series D in Nov 2025.

PMV mark · valuation
$260.3M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$384.5M
Last round
Later Stage VC (Series D)
Nov 2025
What is Artios worth?
$260.3MPrivateMarketView mark · Oct 2026

Valued at $260.3M at its later-stage round, Nov 2025. Nothing has traded since.

Free account
More of Artios with a free account
  • ·The complete investor list: 27 names
  • ·Watch Artios: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Artios funding history

1 rounds
DateRoundRaisedPost-money
Nov 2025Later Stage VC (Series D)$114.4M▮
Unlock post-money valuations

Membership and data by Private Market View

Artios valuation

Artios was valued at $260 million at its later-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Artios raised?

Artios has raised $385 million in total; 1 of its rounds is on record. The largest on record was an $114 million Series D in Nov 2025.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Convergent Therapeutics ($280 million), Edison Scientific ($255 million) and Wugen ($245 million).

How Artios's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Artios, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Artios

What is Artios worth?
Artios is valued at $260.3M as of Oct 2026. Valued at $260.3M at its later-stage round, Nov 2025. Nothing has traded since.
How much has Artios raised?
Artios has raised $384.5M in total funding across 1 recorded rounds.
When did Artios last raise?
Artios last raised in Nov 2025 (Later Stage VC (Series D)), raising $114.4M.